Q2 FY2026 EarningsQ2 FY26 results significantly beat consensus, with revenue of $4.29B vs. $3.82B expected and non-GAAP EPS of $14.29 vs. $10.21 mean estimate. The top-line beat was driven by a 51% surge in Sanofi collaboration revenue (Dupixent sales up 38% YoY) and strong U.S. EYLEA HD sales (+52% YoY). Despite a temporary manufacturing interruption in Ireland impacting GAAP gross margins, non-GAAP margins remained robust, and the full repayment of the Sanofi Development Balance sets the stage for a profit step-up in Q3 FY26.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Regeneron Pharma(REGN) the Revenue is 4.291 B (+16.73%), Beat estimate;the EBIT is 1.653 B (+21.22%), Beat estimate;the EPS is 12.23 (-4.53%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
4.29B16.73%
3.82B4.02%
+0.47B12.71%
EBITExceed expectations
1.65B21.22%
1.19B13.01%
+0.47B34.23%
EPSExceed expectations
12.234.53%
8.728331.86%
+3.501727.33%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf